These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9669358)

  • 1. Modern aspects of prophylaxis and therapy for venous thrombo-embolic disease.
    Bergqvist D
    Aust N Z J Surg; 1998 Jul; 68(7):463-8. PubMed ID: 9669358
    [No Abstract]   [Full Text] [Related]  

  • 2. Ardeparin and danaparoid for prevention of deep vein thrombosis.
    Med Lett Drugs Ther; 1997 Oct; 39(1011):94-5. PubMed ID: 9379998
    [No Abstract]   [Full Text] [Related]  

  • 3. New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
    Boneu B
    Haemostasis; 1996 Oct; 26 Suppl 4():368-78. PubMed ID: 8979141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
    Chirurg; 1998 Nov; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylaxis of venous thromboembolism in stroke patients.
    Turpie AG
    Semin Thromb Hemost; 1997; 23(2):155-7. PubMed ID: 9200340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ardeparin and danaparoid.
    Dimens Crit Care Nurs; 2000; 19(4):13-4. PubMed ID: 11998151
    [No Abstract]   [Full Text] [Related]  

  • 7. Danaparoid is not a low-molecular-weight heparin.
    Nicholson CD; Meuleman DG; Magnani HN; Egberts JF; Leibowitz DA; Spinler SA; Cziraky MJ
    Am J Hosp Pharm; 1994 Aug; 51(16):2049-50. PubMed ID: 7526686
    [No Abstract]   [Full Text] [Related]  

  • 8. Vascular drugs in the new millennium.
    Frangos SG; Chen AH; Sumpio B
    J Am Coll Surg; 2000 Jul; 191(1):76-92. PubMed ID: 10898187
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review).
    Counsell C; Sandercock P
    Stroke; 2002 Jul; 33(7):1925-6. PubMed ID: 12105377
    [No Abstract]   [Full Text] [Related]  

  • 10. Recurrence of venous thromboembolism after treatment with unfractionated heparin.
    Sutton SK
    Ann Intern Med; 1996 Mar; 124(5):532. PubMed ID: 8602716
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of venous thrombosis prophylaxis following ischemic stroke: an assessment of currently available literature.
    Wade WE
    Thromb Res; 1998 Feb; 89(4):199-202. PubMed ID: 9651147
    [No Abstract]   [Full Text] [Related]  

  • 12. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine.
    Leyvraz P; Bachmann F; Bohnet J; Breyer HG; Estoppey D; Haas S; Hochreiter J; Jakubek H; Mair J; Sorensen R
    Br J Surg; 1992 Sep; 79(9):911-4. PubMed ID: 1422754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
    Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
    Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anticoagulant therapy in pulmonary embolism].
    Charbonnier B; Pacouret G; Augusseau-Richard MP; Dessenne X; Pagot O
    Arch Mal Coeur Vaiss; 1995 Nov; 88(11 Suppl):1755-61. PubMed ID: 8815836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When can the patient with deep venous thrombosis begin to ambulate?
    Aldrich D; Hunt DP
    Phys Ther; 2004 Mar; 84(3):268-73. PubMed ID: 14984299
    [No Abstract]   [Full Text] [Related]  

  • 16. The antithrombotic efficacy of dextran.
    Ljungström KG
    Acta Chir Scand Suppl; 1988; 543():26-30. PubMed ID: 2461016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation in continuous renal replacement therapy.
    Vargas Hein O; Kox WJ; Spies C
    Contrib Nephrol; 2004; 144():308-16. PubMed ID: 15264419
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk factors for bleeding during treatment of acute venous thromboembolism.
    Wester JP; de Valk HW; Nieuwenhuis HK; Brouwer CB; van der Graaf Y; Meuwissen OJ; Hart HC; Sixma JJ; Banga JD
    Thromb Haemost; 1996 Nov; 76(5):682-8. PubMed ID: 8950773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosaminoglycans in prophylaxis against venous thromboembolism.
    Bergqvist D; Lindblad B; Mätzsch T
    Adv Exp Med Biol; 1992; 313():259-74. PubMed ID: 1279950
    [No Abstract]   [Full Text] [Related]  

  • 20. New therapeutic options in DVT prophylaxis.
    Wille-Jørgensen P
    Orthopedics; 2000 Jun; 23(6 Suppl):s639-42. PubMed ID: 10875428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.